Informed deferral: A moral requirement for entry into the hepatitis C virus treatment warehouse†
Article first published online: 31 OCT 2012
Copyright © 2012 American Association for the Study of Liver Diseases
Volume 56, Issue 5, pages 1591–1592, November 2012
How to Cite
Aronsohn, A. and Jensen, D. (2012), Informed deferral: A moral requirement for entry into the hepatitis C virus treatment warehouse. Hepatology, 56: 1591–1592. doi: 10.1002/hep.25957
Potential conflict of interest: Dr. Jensen consults for and received grants from Abbott, Bristol-Myers Squibb, Boehringer-Ingelheim, Genentech, and Tibotec. He consults for Astex, Biotica, Gilead, Inhibitex, and Merck. He also have others interests with Consensus Medical Communication and Clinical Care Options.
- Issue published online: 31 OCT 2012
- Article first published online: 31 OCT 2012
- Accepted manuscript online: 13 JUL 2012 04:23PM EST
- Manuscript Accepted: 17 JUN 2012
- 4Principles of Biomedical Ethics. 5th ed. New York, NY: Oxford University Press; 2001., .
- 5Source Book in Bioethics: A Documentary History. Washington, DC: Georgetown University Press; 1998., , .
- 6A History and Theory of Informed Consent. New York, NY: Oxford University Press; 1986., .
- 7Schloendorff v Society of the New York Hospital, 211 N.Y. 125, 105 NE 92 ( 1914).